Allosteric regulation of metabolism in cancer: endogenous mechanisms and considerations for drug design

Current Opinion in Biotechnology

Volumn 48, Issue , 2017, Pages 102-110

  Macpherson, Jamie A ^a   Anastasiou, Dimitrios ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENE EXPRESSION; MOLECULES; PHYSIOLOGY;

ALLOSTERIC MECHANISMS; ALLOSTERIC PROPERTIES; ALLOSTERIC REGULATION; ENERGY METABOLISM; INTRACELLULAR SIGNALLING; METABOLIC ADAPTATION; METABOLIC PROCESS; PROTEIN INTERACTION;

METABOLISM;

LIGAND;

ALLOSTERISM; DRUG DESIGN; ENERGY METABOLISM; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASM; METABOLIC REGULATION; METABOLITE; MOLECULAR INTERACTION; MOLECULAR SIZE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; METABOLISM; NEOPLASM;

ALLOSTERIC REGULATION; DRUG DESIGN; ENERGY METABOLISM; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 85017623215     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2017.03.022     Document Type: Review

References (79)

1. 1 Gerosa, L., Sauer, U., Regulation and control of metabolic fluxes in microbes. Curr. Opin. Biotechnol. 22 (2011), 566–575.
2. 2 Changeux, J.P., Allostery and the Monod–Wyman–Changeux model after 50 years. Annu. Rev. Biophys. 41 (2012), 103–133.
3. 3 Li, X., Chen, Y., Lu, S., Huang, Z., Liu, X., Wang, Q., et al. Toward an understanding of the sequence and structural basis of allosteric proteins. J. Mol. Graphics Modell. 40 (2013), 30–39.
4. 4 DeBerardinis, R.J., Chandel, N.S., Fundamentals of cancer metabolism. Sci Adv., 2, 2016, e1600200.
5. 5 Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476 (2011), 346–350.
6. 6 Locasale, J.W., Grassian, A.R., Melman, T., Lyssiotis, C.A., Mattaini, K.R., Bass, A.J., et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43 (2011), 869–874.
7. 7 DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S., Dang, L., Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem. Biol. 21 (2014), 1143–1161.
8. 8 Sullivan, L.B., Gui, D.Y., Vander Heiden, M.G., Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat. Rev. Cancer 16 (2016), 680–693.
9. 9 Jurica, M.S., Mesecar, A., Heath, P.J., Shi, W., Nowak, T., Stoddard, B.L., The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 6 (1998), 195–210.
10. 10 Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C.L., Maddocks, O.D.K., Chokkathukalam, A., et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491 (2012), 458–462.
11. 11 Keller, K.E., Tan, I.S., Lee, Y.-S., SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338 (2012), 1069–1072.
12. 12 Morgan, H.P., O'Reilly, F.J., Wear, M.A., O'Neill, J.R., Fothergill-Gilmore, L.A., Hupp, T., et al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 5881–5886.
13. 13 Ashizawa, K., Kato, H., McPhie, P., Cheng, S., Regulation of thyroid hormone binding to its cytosolic binding protein by L-alpha-alanine. Biochem. Biophys. Res. Commun. 167 (1990), 587–592.
14. 14 Christofk, H.R., Vander Heiden, M.G., Wu, N., Asara, J.M., Cantley, L.C., Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452 (2008), 181–186.
15. 15 Lu, W., Cao, Y., Zhang, Y., Li, S., Gao, J., Wang, X.-A., et al. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci. Rep., 6, 2016, 26351.
16. 16 Yu, G., Yu, W., Jin, G., Xu, D., Chen, Y., Xia, T., et al. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol. Cancer, 14, 2015, 193.
17. 17•• Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.-K., Boxer, M.B., Hong, B.S., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8 (2012), 839–847 This study provided the first comprehensive investigation into the structural binding modes of two classes of small-molecule PKM2 activators and their effect on tumour growth.
18. 18 Israelsen, W.J., Dayton, T.L., Davidson, S.M., Fiske, B.P., Hosios, A.M., Bellinger, G., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155 (2013), 397–409.
19. 19 Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008), 230–233.
20. 20 Schieber, M., Chandel, N.S., ROS function in redox signaling and oxidative stress. Curr. Biol. 24 (2014), R453–R462.
21. 21 Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.-k., Shen, M., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334 (2011), 1278–1283.
22. 22 Snell, K., Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv. Enzyme Regul. 22 (1984), 325–400.
23. 23 Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005), 864–870.
24. 24 Nikiforov, M.A., Chandriani, S., O'Connell, B., Petrenko, O., Kotenko, I., Beavis, A., et al. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol. Cell Biol. 22 (2002), 5793–5800.
25. 25 Kim, D., Fiske, B.P., Birsoy, K., Freinkman, E., Kami, K., Possemato, R.L., et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520 (2015), 363–367.
26. 26 Boxer, M.B., Jiang, J.-k., Vander Heiden, M.G., Shen, M., Skoumbourdis, A.P., Southall, N., et al. Evaluation of substituted N,N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 53 (2010), 1048–1055.
27. 27 Jiang, J.-k., Boxer, M.B., Vander Heiden, M.G., Shen, M., Skoumbourdis, A.P., Southall, N., et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 20 (2010), 3387–3393.
28. 28 Guo, C., Linton, A., Jalaie, M., Kephart, S., Ornelas, M., Pairish, M., et al. Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg. Med. Chem. Lett. 23 (2013), 3358–3363.
29. 29 Kung, C., Hixon, J., Choe, S., Marks, K., Gross, S., Murphy, E., et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19 (2012), 1187–1198.
30. 30 Yacovan, A., Ozeri, R., Kehat, T., Mirilashvili, S., Sherman, D., Aizikovich, A., et al. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 22 (2012), 6460–6468.
31. 31 Parnell, K.M., Foulks, J.M., Nix, R.N., Clifford, A., Bullough, J., Luo, B., et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 12 (2013), 1453–1460.
32. 32 Naithani, A., Taylor, P., Erman, B., Walkinshaw, M.D., A molecular dynamics study of allosteric transitions in Leishmania mexicana pyruvate kinase. Biophys. J. 109 (2015), 1149–1156.
33. 33 Donovan, K.A., Zhu, S., Liuni, P., Peng, F., Kessans, S.A., Wilson, D.J., et al. Conformational dynamics and allostery in pyruvate kinase. J. Biol. Chem. 291 (2016), 9244–9256.
34. 34• Novellasdemunt, L., Tato, I., Navarro-Sabate, A., Ruiz-Meana, M., Mendez-Lucas, A., Perales, J.C., et al. Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB2) isoenzyme by amino acids. J. Biol. Chem. 288 (2013), 10640–10651 PI3K and p38 signalling converge at Akt to activate phosphofructokinase-2 and the production of fructose-2,6-bisphosphate. An excellent demonstration of how signalling and metabolism are intimately linked.
35. 35 Lawson, J.W., Uyeda, K., Effects of insulin and work on fructose 2,6-bisphosphate content and phosphofructokinase activity in perfused rat hearts. J. Biol. Chem. 262 (1987), 3165–3173.
36. 36 Cantley, L.C., Neel, B.G., New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 4240–4245.
37. 37 Cordero-Espinoza, L., Hagen, T., Increased concentrations of fructose 2,6-bisphosphate contribute to the Warburg effect in phosphatase and tensin homolog (PTEN)-deficient cells. J. Biol. Chem. 288 (2013), 36020–36028.
38. 38 Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K., Tavare, J.M., The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 277 (2002), 33895–33900.
39. 39 Bauer, D.E., Hatzivassiliou, G., Zhao, F., Andreadis, C., Thompson, C.B., ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24 (2005), 6314–6322.
40. 40• Webb, B.A., Forouhar, F., Szu, F.-E., Seetharaman, J., Tong, L., Barber, D.L., Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations. Nature 523 (2015), 111–114 The first reported crystal structure of full-length phosphofructokinase-1 bound to citrate and ATP. The authors found that cancer-associated mutations at allosteric sites (R48C and M426S) act to reduce allosteric inhibition by citrate and ATP, respectively.
41. 41 Hong, S.P., Leiper, F.C., Woods, A., Carling, D., Carlson, M., Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 8839–8843.
42. 42 Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13 (2003), 2004–2008.
43. 43 Woods, A., Dickerson, K., Heath, R., Hong, S.P., Momcilovic, M., Johnstone, S.R., et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2 (2005), 21–33.
44. 44 Xie, M., Zhang, D., Dyck, J.R., Li, Y., Zhang, H., Morishima, M., et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 17378–17383.
45. 45 Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., Carling, D., et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271 (1996), 27879–27887.
46. 46 Sanders, M.J., Grondin, P.O., Hegarty, B.D., Snowden, M.A., Carling, D., Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403 (2007), 139–148.
47. 47•• Xiao, B., Heath, R., Saiu, P., Leiper, F.C., Leone, P., Jing, C., et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449 (2007), 496–500 Investigation into the structural basis of AMP binding to the γ-subunit of AMPK. Structural and biophysical studies found that the phosphate groups of AMP and ATP bind within grooves between tandem Bateman domains of the γ-subunit.
48. 48• Xiao, B., Sanders, M.J., Underwood, E., Heath, R., Mayer, F.V., Carmena, D., et al. Structure of mammalian AMPK and its regulation by ADP. Nature 472 (2011), 230–233 Herein the authors describe the structural basis of ADP binding to the γ-subunit of AMPK and the mechanism by which it protects the enzyme against dephosphorylation of Thr-172.
49. 49 Carling, D., Mayer, F.V., Sanders, M.J., Gamblin, S.J., AMP-activated protein kinase: nature's energy sensor. Nat. Chem. Biol. 7 (2011), 512–518.
50. 50 Park, S.H., Gammon, S.R., Knippers, J.D., Paulsen, S.R., Rubink, D.S., Winder, W.W., Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J. Appl. Physiol. (1985) 92 (2002), 2475–2482.
51. 51 Zibrova, D., Vandermoere, F., Goransson, O., Peggie, M., Marino, K., Knierim, A., et al. GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. Biochem. J. 474 (2016), 983–1001.
52. 52 Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol. Cell. 49 (2013), 1167–1175.
53. 53 Hayashi, T., Hirshman, M.F., Kurth, E.J., Winder, W.W., Goodyear, L.J., Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47 (1998), 1369–1373.
54. 54 Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3 (2006), 403–416.
55. 55 Sanders, M.J., Ali, Z.S., Hegarty, B.D., Heath, R., Snowden, M.A., Carling, D., Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282 (2007), 32539–32548.
56. 56• Xiao, B., Sanders, M.J., Carmena, D., Bright, N.J., Haire, L.F., Underwood, E., et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun., 4, 2013, 3017 A structural investigation into the binding modes of AMPK small-molecule activators and their biophysical mechanism of AMPK activation.
57. 57•• Yang, J.-S., Seo, S.W., Jang, S., Jung, G.Y., Kim, S., Rational engineering of enzyme allosteric regulation through sequence evolution analysis. PLoS Comput. Biol., 8, 2012, e1002612 This study shows that allosteric sites are more sequence variable than catalytic pockets and are composed of more hydrophobic residues, as compared to orthosteric binding sites.
58. 58 Capra, J.A., Laskowski, R.A., Thornton, J.M., Singh, M., Funkhouser, T.A., Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. PLoS Comput. Biol., 5, 2009, e1000585.
59. 59 Nussinov, R., Tsai, C.-J., The design of covalent allosteric drugs. Annu. Rev. Pharmacol. Toxicol. 55 (2015), 249–267.
60. 60 Reinhard, F.B., Eberhard, D., Werner, T., Franken, H., Childs, D., Doce, C., et al. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat. Methods 12 (2015), 1129–1131.
61. 61•• Lockless, S.W., Ranganathan, R., Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286 (1999), 295–299 Seminal work describing a generalistic method used to measure the statistcal coupling between distal amino acid residues from large multiple sequence alignments.
62. 62 Suel, G.M., Lockless, S.W., Wall, M.A., Ranganathan, R., Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat. Struct. Biol. 10 (2003), 59–69.
63. 63 Hatley, M.E., Lockless, S.W., Gibson, S.K., Gilman, A.G., Ranganathan, R., Allosteric determinants in guanine nucleotide-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 14445–14450.
64. 64• Reynolds, K.A., McLaughlin, R.N., Ranganathan, R., Hot spots for allosteric regulation on protein surfaces. Cell 147 (2011), 1564–1575 Authors use a previously described aroach (61) for uncovering surface-exposed allosteric residues in dihydrofolate reductase, which were then used as target points for the engineering of a light-inducible LOV2 domain.
65. 65 Halabi, N., Rivoire, O., Leibler, S., Ranganathan, R., Protein sectors: evolutionary units of three-dimensional structure. Cell 138 (2009), 774–786.
66. 66 Hudson, J.W., Golding, G.B., Crerar, M.M., Evolution of allosteric control in glycogen phosphorylase. J. Mol. Biol. 234 (1993), 700–721.
67. 67•• Pandini, A., Fornili, A., Kleinjung, J., Structural alphabets derived from attractors in conformational space. BMC Bioinformatics, 11, 2010, 97 Authors cluster a minimal set of protein structures from the protein data bank using a fragment-based approach and derive an alphabet of structural fragments, which are able to accurately describe the conformation of protein folds.
68. 68 Pandini, A., Fornili, A., Fraternali, F., Kleinjung, J., GSATools: analysis of allosteric communication and functional local motions using a structural alphabet. Bioinformatics 29 (2013), 2053–2055.
69. 69 Pandini, A., Fornili, A., Using local states to drive the sampling of global conformations in proteins. J. Chem. Theory Comput. 12 (2016), 1368–1379.
70. 70 Pandini, A., Bonati, L., Fraternali, F., Kleinjung, J., MinSet: a general approach to derive maximally representative database subsets by using fragment dictionaries and its application to the SCOP database. Bioinformatics 23 (2007), 515–516.
71. 71•• Pandini, A., Fornili, A., Fraternali, F., Kleinjung, J., Detection of allosteric signal transmission by information-theoretic analysis of protein dynamics. FASEB J. 26 (2012), 868–881 Using molecular dynamics simulations and analysis tools developed in (68), the authors elucidate the allosteric mechanism of three small bacterial proteins.
72. 72 Baussand, J., Kleinjung, J., Specific conformational states of Ras GTPase upon effector binding. J. Chem. Theory Comput. 9 (2013), 738–749.
73. 73 Lin, J.H., Perryman, A.L., Schames, J.R., McCammon, J.A., Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J. Am. Chem. Soc. 124 (2002), 5632–5633.
74. 74 Guvench, O., MacKerell, A.D. Jr., Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput. Biol., 5, 2009, e1000435.
75. 75 Huang, D., Caflisch, A., Small molecule binding to proteins: affinity and binding/unbinding dynamics from atomistic simulations. ChemMedChem 6 (2011), 1578–1580.
76. 76 Miao, Y., Goldfeld, D.A., Moo, E.V., Sexton, P.M., Christopoulos, A., McCammon, J.A., et al. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E5675–E5684.
77. 77• Shen, Q., Wang, G., Li, S., Liu, X., Lu, S., Chen, Z., et al. ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res. 44 (2016), D527–D535 A unique database that curates known allosteric proteins as well as small molecule allosteric ligands.
78. 78 Licata, L., Briganti, L., Peluso, D., Perfetto, L., Iannuccelli, M., Galeota, E., et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 40:Database issue (2012), D857–D861.
79. 79 Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.